Joanne Berger-Sweeney
Joanne E. Berger-Sweeney (born September 21, 1958) is an American neuroscientist and the 22nd president of Trinity College, Hartford, Connecticut. She is the first African-American and the first woman to serve in the position. Earlier in her career, Berger-Sweeney did proof-of-concept work on galantamine (brand name Razadyne), the second-most used drug to treat Alzheimer's disease.
Joanne Berger-Sweeney | |
|---|---|
Joanne Berger-Sweeney in 2012 | |
| Born | Joanne E. Sweeney September 21, 1958 Los Angeles, California |
| Nationality | American |
| Education | Wellesley College (1979 BA) UC Berkeley (1981 MPH) Johns Hopkins Bloomberg School of Public Health (1989 PhD) |
| Known for | Proof-of-concept work on galantamine, a drug used to treat Alzheimer's disease |
| Spouse | Urs V. Berger |
| Children | 2 |
| Awards | Alumni Achievement Award, Johns Hopkins University (2015) Posse Star, Posse Foundation (2017) |
| Scientific career | |
| Fields | Neuroscience |
| Institutions | Trinity College (Connecticut) |
| Doctoral advisor | Joseph T. Coyle Yvon Lamour |
| Doctoral students | Elizabeth A. Buffalo |
| Signature | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.